Last reviewed · How we verify
Antithrombotics
Antithrombotics is a Small molecule drug developed by Pain Management Center of Paducah. It is currently in Phase 2 development. Also known as: anticoagulant or antiplatelet drugs.
Antithrombotic agents are drugs that reduce the formation of blood clots (thrombi) and are used to prevent or treat various conditions, including Venous Thromboembolism, Stroke, and Myocardial Infarction. These small molecule drugs, such as Rivaroxaban and Dabigatran, are used to treat and prevent a variety of diseases, as per clinical guidelines published by the American College of Chest Physicians.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Antithrombotics |
|---|---|
| Also known as | anticoagulant or antiplatelet drugs |
| Sponsor | Pain Management Center of Paducah |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION) (PHASE4)
- SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke (PHASE4)
- Delayed IntraCranial Hemorrhage in Oral AntiCoagulant Treated Patients With Mild Traumatic Brain Injury
- Randomized On-X Anticoagulation Trial (NA)
- Qualitative Analysis of Interviews Between Pharmacist and Elderly Patients Treated with Antithrombotics for an Ischemic Stroke.
- Antithrombotics' Therapeutic Optimization in Hospitalized Patients Using Physiologically- and Population-based Pharmacokinetic Modeling
- Major Bleeding Risk Associated With Antithrombotics
- The Bleeding With Antithrombotic Therapy Study 2
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antithrombotics CI brief — competitive landscape report
- Antithrombotics updates RSS · CI watch RSS
- Pain Management Center of Paducah portfolio CI
Frequently asked questions about Antithrombotics
What is Antithrombotics?
Who makes Antithrombotics?
Is Antithrombotics also known as anything else?
What development phase is Antithrombotics in?
Related
- Manufacturer: Pain Management Center of Paducah — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Also known as: anticoagulant or antiplatelet drugs
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing